Skip to main content
TipRanks
Go Ultimate75% OFF

STELLA PHARMA CORPORATION (4888) AI Stock Analysis

0 Followers
JP:4888

STELLA PHARMA CORPORATION

(TSE/TYO:4888)

Select Model
Rating:43Neutral
Price Target:JPY 333.00â–¼(-6.20% Downside)
Action:reiterated
Date:10/09/26

The overall score is low, driven primarily by weak financial performance. Persistent net losses, highly volatile revenue, and negative cash flows are significant risks. The balance sheet provides some stability, but it is not enough to offset the poor income and cash flow trends. Technicals are neutral and valuation is unsupportive due to negative earnings.

Positive Factors
Manageable LeverageRecent leverage appears manageable and capitalization improved substantially from the elevated 2021 profile. This gives the company more financial flexibility than its historical position, although continued losses mean balance-sheet strength must be preserved through disciplined liquidity management.
Negative Factors
Sharp Revenue ContractionThe sharp revenue decline creates substantial uncertainty around demand, commercial execution, and near-term business scale. Volatile top-line performance makes fixed-cost absorption harder, weakens earnings visibility, and limits confidence that the company can sustain investment or build a durable growth trajectory.

STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)

-50%0%50%100%150%200%250%JP:4888+39.76%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 13.50B
Dividend Yield
―
Average Volume (3M)
427.21K
Price to Earnings (P/E)
-14.3
Beta (1Y)
1.06
Revenue Growth
-69.92%
EPS Growth
-411.54%
Country
Japan
Employees
47
Sector
General
Sector Strength
55
Industry
Biotechnology

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company Description

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy...

STELLA PHARMA CORPORATION Financial Statement Overview

Summary

Financial performance is weak. The income statement shows persistent losses and highly volatile revenue, with a 66% drop in the latest year. Cash flow is predominantly negative, indicating a cash-burning business. The balance sheet is the only relative bright spot, with manageable debt, but overall financial health is poor.

Income Statement

22Negative

Balance Sheet

58Neutral

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue323.39M323.39M961.06M269.49M229.07M100.10M
Gross Profit264.07M250.56M828.72M203.69M192.36M50.73M
EBITDA-832.87M-742.15M-99.06M-723.85M-738.35M-726.86M
Net Income-853.06M-780.92M-140.81M-763.75M-778.82M-767.72M
Balance Sheet
Total Assets5.39B4.49B5.42B3.82B4.33B4.72B
Cash, Cash Equivalents and Short-Term Investments3.80B2.82B3.21B2.35B2.71B3.28B
Total Debt899.48M747.14M766.78M933.30M1.09B1.25B
Total Liabilities2.17B2.06B2.21B1.44B1.58B1.64B
Stockholders Equity3.22B2.43B3.21B2.38B2.75B3.08B
Cash Flow
Free Cash Flow0-345.32M136.50M-887.82M-853.07M-1.13B
Operating Cash Flow0-334.51M140.41M-876.84M-827.67M-1.08B
Investing Cash Flow0-15.67M287.58M-9.01M-29.93M-350.56M
Financing Cash Flow0-33.28M725.78M228.25M291.69M3.46B

STELLA PHARMA CORPORATION Technical Analysis

Technical Analysis SentimentNegative
Last Price355.00

Price Trends

50DMA400.74Negative
100DMA362.30Negative
200DMA417.23Negative

Market Momentum

MACD-12.50Positive
RSI39.83Neutral
STOCH29.80Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Negative. The current price of 355.00 is below the 20-day moving average (MA) of 395.35, below the 50-day MA of 400.74, and below the 200-day MA of 417.23, indicating a bearish trend. The MACD of -12.50 indicates Positive momentum. The RSI at 39.83 is Neutral, neither overbought nor oversold. The STOCH value of 29.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4888 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4888JP:488843NeutralJPY 13.50B-14.26――-69.92%-411.54%
JP:7774JP:777442NeutralJPY 26.52B-73.78――17.05%10.47%
JP:4571JP:457141NeutralJPY 6.10B-4.98-33.61%―48.92%-46.91%
JP:4593JP:459339UnderperformJPY 30.90B-13.76――-51.55%52.19%
JP:4599JP:459938UnderperformJPY 7.33B-3.94―――4.85%

* General Sector Average

Performance Comparison

0%100%200%JP:4888JP:4571JP:4593JP:4599JP:7774Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4888 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4888STELLA PHARMA CORPORATION355.00111.0045.49%
JP:4571NanoCarrier Co., Ltd.67.00-83.00-55.33%
JP:4593Healios KK228.00-223.00-49.45%
JP:4599StemRIM Inc.117.00-161.00-57.91%
JP:7774Japan Tissue Engineering Co., Ltd.653.00175.0036.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 09, 2026